Bromethalin is a central nervous system toxin currently incorporated into several different rodenticides. In 2008, the EPA requested that manufacturers phase out second-generation anticoagulant rodenticides. In response, manufacturers began to increase production of bromethalin-based rodenticides. It is likely that pet exposure to bromethalin will increase in the future. Bromethalin has no known antidote and tends to deposit in fat. Intravenous lipid emulsions (ILEs) are being used with increasing frequency in both human and veterinary medicine to treat numerous acute systemic toxicities. A 4 yr old spayed female Pit bull terrier was presented following witnessed ingestion of bromethalin rodenticide by the owners. Decontamination was unsuccessful and ILE was started. Serum was frozen at À808C before and 1 hr after completion of ILE. In rats, the half-life of desmethylbromethalin, the toxic metabolite, has been reported at 5.6 days and 6 days, and it is likely to be similar in dogs. The only intervention between the pre-lipid serum sample and the post-lipid serum sample was the administration of ILE, and the serum desmethylbromethalin levels were reduced by 
Introduction
Bromethalin (2,4- com). 2 Due to the concern about accidental ingestion by children and pets, some countries, such as Canada, have placed regulations on methods of baiting with bromethalin. 3 Bromethalin is a rapidly acting toxin with no known antidote.
Metabolism of bromethalin has been studied in rats, and it has been shown that peak plasma concentrations of the metabolite, desmethylbromethalin, occur within 4 h after ingestion. 4 Hepatic metabolism converts bromethalin to the more toxic metabolite, desmethylbromethalin, rapidly. Its principal mechanism of action is to uncouple mitochondrial oxidative phosphorylation, and it reaches its highest concentration in body fat. 5 The oral lethal dose 50 in dogs has been reported to be 3.7 mg/kg, but it is possible that individual dogs could develop clinical signs following exposure to just one-tenth of the oral lethal does 50. 6, 7 Bromethalin excretion is primarily in the bile, and prevention of enterohepatic recirculation along with supportive care are the mainstays of treatment. This report describes the use of ILE to treat bromethalin ingestion in a dog. While in the hospital, the dog had a single bowel movement in which flecks of green material resembling rodenticide could be seen. Therefore, it was determined that the dog had likely consumed additional rodenticide prior to the witnessed event.
Case Report
After speaking with ASPCA Poison Control, it was determined that 2 oz of the bait would reach the low end of the toxic dose for this dog, and it was assumed that the patient had consumed at least this amount. The owners later reported that it was possible that two blocks of rodenticide were missing from their yard.
Upon presentation, the dog was bright, alert, responsive, and Intravenous apomorphine at 0.03 mg/kg was administered twice and failed to produce emesis both times. An intravenous catheter was placed and ILE was administered at 1.5 ml/kg given over the first 20 min followed by 0.38 ml/kg/min for 60 min. Serum was obtained for desmethylbromethalin levels 1 h following administration of the intravenous lipids and was immediately frozen at À808F until analysis. After the second sample was collected, isotonic crystalloids were started at 5 ml/kg/h intravenously and were continued throughout the night. Activated charcoal was administered by mouth at 7.3 ml/kg every 6 h.
The dog was kept hospitalized with supportive care for 24 h, during which no neurologic abnormalities were noted. After 24 h, the owner elected to take the patient home for continued monitoring because of financial reasons. The owner reported the dog was acting normally at a 2 wk follow-up call. 
Discussion
To the authors' knowledge, this is the first report describing treatment of bromethalin ingestion with ILE. Although the actual ingested dose is unknown, it is likely to have been a minimum of two bricks, or 5.7 g. The reported half-life of desmethylbromethalin in rats has been reported at 5.6 days and 6 days, and it is likely to be similar in dogs. 1, 4 The only intervention between the pre-lipid serum sample and the post-lipid serum sample was the administration of ILE, and the serum desmethylbromethalin levels were reduced by 75% (from 4 ppb to 1 ppb) during this time. It is therefore likely that the ILE was responsible for the rapid and significant decrease in the desmethylbromethalin levels.
Following ingestion of bromethalin, hepatic metabolism converts it to the more toxic metabolite desmethylbromethalin, and this is then excreted in the bile by enterohepatic circulation, with renal excretion being less than 3%. Reuptake from the bile and intestinal tract causes enterohepatic reabsorption to occur. 1 Due to bromethalin and its metabolite primarily being deposited in fat, the lipophilic nature of bromethalin would make it an ideal toxin to be treated with intravenous lipid therapy. It has been mentioned that there is no specific antidote for bromethalin, and supportive care is the mainstay of therapy. Early decontamination and treatment to prevent gastrointestinal absorption and enterohepatic recirculation are suggested; however, decontamination is not always possible, as in this case. Due to bromethalin's rapid absorption, it is also recommended that patients who have ingested bromethalin more than 1.5 h prior to presentation should not have emesis induced. 1 If emesis is induced within 10 min of ingestion, only 75% of the toxin may be returned. 1 Gastric lavage is no longer recommended due to weak evidence of efficacy.
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Use of activated charcoal has been recommended with bromethalin ingestion, as it has significant enterohepatic recirculation. 1 However, the slow elimination of desmethylbromethalin creates the need to have low doses administered frequently for an extended period of time (1 mg/kg every 4-6 h for 2-3 days).
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Diuresis with intravenous fluids is typically attempted in cases of bromethalin toxicosis but is usually of limited benefit, as only 3% of the toxin is cleared by kidneys. 
Conclusion
The laboratory results demonstrated a dramatic reduction in serum desmethylbromethalin concentrations secondary to ILE administration. We hypothesize that the ILE hastened the removal of the desmethylbromethalin by first attracting it to the lipid compartment and then eliminating it via the biliary system. The lipophilic nature of bromethalin makes it an excellent candidate for this treatment, and this is the only report of an intervention that has rapidly reduced the circulating levels of bromethalin, to the authors' knowledge. ILEs offer a potentially attractive option for the treatment of bromethalin toxicity, and this treatment should be considered in such cases. 
